MF59 adjuvanted SARS-CoV-2 Sclamp vaccine (The University of Queensland/CSL)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMF59 adjuvanted SARS-CoV-2 Sclamp vaccine (The University of Queensland/CSL)
Drug Alias NameaCoV2Adjuvanted SARS-CoV-2 Subunit vaccineUQ-CSL V451
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of QueenslandCsl Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Queensland
Inactive CompaniesSeqirus
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A